These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1000973)

  • 1. A method of computing drug distribution in plasma using stepwise association constants: clofibrate acid as an illustrative example.
    Wosilait WD; Nagy P
    Comput Programs Biomed; 1976 Oct; 6(3):142-8. PubMed ID: 1000973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A method of computing the distribution of a ligand among multiple binding sites on different proteins in plasma: thyroxine as an illustrative example.
    Wosilait WD; Nagy P
    Comput Programs Biomed; 1976 Dec; 6(4):232-37. PubMed ID: 827417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.
    Bjornsson TD; Meffin PJ; Swezey S; Blaschke TF
    J Pharmacol Exp Ther; 1979 Sep; 210(3):316-21. PubMed ID: 480183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution of halofenate in plasma: a comparative analysis using Scatchard vs. stepwise association constants.
    Wosilait WD; Nagy P
    Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):75-81. PubMed ID: 935655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous GLC determination of clofibrate and clofibric acid in human plasma.
    Wolf MS; Zimmerman JJ
    J Pharm Sci; 1980 Jan; 69(1):92-3. PubMed ID: 7354454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of clofibric acid (CPIB) metabolites in plasma of patients on clofibrate therapy.
    Faed EM; McQueen EG
    Clin Exp Pharmacol Physiol; 1979; 6(3):267-73. PubMed ID: 466868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products.
    Altmayer P; Garrett ER
    J Pharm Sci; 1983 Nov; 72(11):1309-18. PubMed ID: 6644594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic assay for the simultaneous determination of ethyl clofibrate and clofibric acid in plasma. Evaluation of plasma stability of ethyl clofibrate polylactic nanocapsules in human and rat plasmas.
    Barra J; Taburet AM; Jardel A; Fessi H; Puisieux F
    J Chromatogr B Biomed Appl; 1994 Nov; 661(1):178-82. PubMed ID: 7866548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gas chromatographic analysis of p-chlorphenoxy-isobutyric acid (clofibrate)].
    Knüchel F; Ochs H
    Arzneimittelforschung; 1974 Apr; 24(4):576-8. PubMed ID: 4408060
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans.
    Taylor T; Chasseaud LF
    J Pharm Sci; 1977 Nov; 66(11):1638-9. PubMed ID: 915750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of high-performance liquid chromatography to measure plasma concentrations of p-chlorophenoxyisobutric acid after administration of clofibrate to humans.
    Woodhouse RN; Cresswell DG; Chasseaud LF; Brodie RR
    J Chromatogr; 1977 Jul; 137(1):218-21. PubMed ID: 893585
    [No Abstract]   [Full Text] [Related]  

  • 12. A rapid gas chromatographic method for the determination of chlorophenoxyisobutyric acid in plasma and urine.
    Gugler R; Jensen C
    J Chromatogr; 1976 Feb; 117(1):175-9. PubMed ID: 1249148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of prolonged clofibrate treatment on the plasma drug concentration and liver NADP-linked enzymes activity.
    Zelewski M; Swierczyński J
    Gen Pharmacol; 1986; 17(1):117-9. PubMed ID: 3949145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats.
    Cayen MN; Robinson WT; Dubuc J; Dvornik D
    Biochem Pharmacol; 1979 Apr; 28(7):1163-7. PubMed ID: 444274
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of free fatty acid concentration on drug binding to plasma albumin.
    Spector AA; Santos EC; Ashbrook JD; Fletcher JE
    Ann N Y Acad Sci; 1973 Nov; 226():247-58. PubMed ID: 4520396
    [No Abstract]   [Full Text] [Related]  

  • 16. Clofibrate and enzymatic induction in man.
    Houin G; Tillement JP
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):150-4. PubMed ID: 649234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of clofibrate in familial hypercholesterolemia.
    Pichardo R; Boulet L; Davignon J
    Atherosclerosis; 1977 Apr; 26(4):573-82. PubMed ID: 193524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters.
    Beaumont JL; Dachet C
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):41-3. PubMed ID: 1019153
    [No Abstract]   [Full Text] [Related]  

  • 19. Clofibrate kinetics after single and multiple doses.
    Gugler R; Hartlapp J
    Clin Pharmacol Ther; 1978 Oct; 24(4):432-8. PubMed ID: 688733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.